Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma

Clinical Cancer Research

Volumn 17, Issue 21, 2011, Pages 6681-6692

  Akter, Jesmin ^a,b   Takatori, Atsushi ^a   Hossain, Md Shamim ^a   Ozaki, Toshinori ^a   Nakazawa, Atsuko ^c   Ohira, Miki ^a   Suenaga, Yusuke ^a   Nakagawara, Akira ^a,b  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; MEMBRANE PROTEIN; MESSENGER RNA; MYC INTERACTING ZINC FINGER PROTEIN 1; NEURONAL LEUCINE RICH REPEAT PROTEIN 3; RETINOIC ACID; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MYCN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC REGULATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MIZ 1 GENE; MOLECULAR MECHANICS; MYCN GENE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NLRR3 ORPHAN RECEPTOR GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REPORTER GENE; TRANSCRIPTION REGULATION; UPREGULATION;

CELL DIFFERENTIATION; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NEUROBLASTOMA; NEURONS; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 80455162361     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0313     Document Type: Article

References (47)

1. Westemann F, Schwab M. Genetic parameters of neuroblastomas. Cancer Lett 2002;184:127-47. (Pubitemid 34804499)
2. Brodeur GM, Nakagawara A. Molecular basis of clinical heterogeneity in neuroblastoma. Am J Pediatr Hematol Oncol 1992;14:111-6.
3. Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992;52:1364-68.
4. Nakagawara A, Arima-Nakagwara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. New Engl J Med 1993;328:847-54. (Pubitemid 23084339)
5. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994;14:759-67.
6. Nakagawara A, Arima-Nakagawara M, Azar CG, Scavarda NJ, Brodeur GM. Clinical significance of expression of neurotrophic factors and their receptors in neuroblastoma. Prog Clin Biol Res 1994;385:155-61.
7. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Associations of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. New Engl J Med 1985;313:1111-6. (Pubitemid 16216827)
8. Kohl NE, Gee CE, Alt FW. Activated expression of the N-myc gene in human neuroblastomas and related tumors. Science 1984;226:1335-7. (Pubitemid 15215589)
9. Nisen PD, Waber PG, Rich MA, Pierce S, Garvin JR, Gilbert F, et al. Nmyc oncogene RNA expression in neuroblastoma. J Natl Cancer Inst 1988;80:1633-7. (Pubitemid 19006814)
10. Slavc I, Ellenbogen R, Jung WH, Vawter GF, Kretschmar C, Grier H, et al. Myc gene amplification and expression in primary human neuroblastoma. Cancer Res 1990;50:1459-63. (Pubitemid 20090455)
11. Seeger RC, Wada R, Brodeur GM, Moss TJ, Bjork RL, Sousa L, et al. Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res 1988;271:41-9.
12. Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci U S A 1984;81:4940-4.
13. Cohn SL, Tweddle DA. MYCN amplification remains prognostically strong 20 years after its "clinical debut". Eur J Cancer 2004;40:2639-42. (Pubitemid 39574716)
14. Strieder V, Lutz W. Regulation of N-myc expression in development and diseases. Cancer Lett 2002;180:107-19. (Pubitemid 34327363)
15. Kouzarides T, Ziff E. The role of the leucine zipper in the fos-jun interaction. Nature 1988;336:646-51. (Pubitemid 19007944)
16. Landschulz WH, Johnson PF, Mcknight SL. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 1988;240:1759-64.
17. Alex R, Sozeri O, Meyer S, Dildrop R. Determination of the DNA sequence recognized by the bHLH-zip domain of the N-Myc protein. Nucleic Acids Res 1992;20:2257-63.
18. Blackwood EM, Kretzner L, Eisenman RN. Myc and Max function as a nucleoprotein complex. Curr Opin Genet Dev 1992;2:227-35.
19. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nature Cell Biol 2001;3:392-9. (Pubitemid 32288447)
20. Wu S, Cetinkaya C, Munoz-Alonso MJ, Von der Lehr N, Bahram F, Beuger V, et al. Myc represses differentiation-induced p21CIPI expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene 2003;22:351-60. (Pubitemid 36194331)
21. Zhang J, Li F, Liu X, Shen L, Liu J, Su J, et al. The repression of human differentiated-related gene NDRG2 expression by Myc via Miz-1 dependent interaction with the NDRG2 core promoter. J Biol Chem 2006;281:39159-68. (Pubitemid 46041876)
22. Koppen A, Ait-Aissa R, Hopman S, Koster J, Haneveld F, Versteeg R, et al. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation. Cancer Lett 2007;256:218-28. (Pubitemid 47418350)
23. Hamano S, Ohira M, Isogai E, Nakada K, Nakagawara A. Identification of novel human neuronal leucine-rich repeat (hNLRR) family genes and inverse association of expression of Nbla10449/hNLRR-1 and Nbla10677/hNLRR-3 with the prognosis of primary neuroblastomas. Int J Oncol 2004;24:1457-66.
24. Ohira M, Morohashi A, Inuzuka H, Shishikura T, Kawamoto T, Kageyama H, et al. Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets. Oncogene 2003;22:5525-36. (Pubitemid 37072208)
25. Hayata T, Uochi T, Asashima M. Molecular cloning of XNLRR-1, a Xenopus homolog of mouse neuronal leucine-rich repeat protein expressed in the developing Xenopus nervous system. Gene 1998;221:159-66. (Pubitemid 28529620)
26. Fukamachi K, Matsuoka Y, Ohno H, Hamaguchi T, Tsuda H. Neuronal leucine-rich repeat protein-3 amplifies MAPK activation by epidermal growth factor through a carboxyl-terminal region containing endocytosis motifs. J Biol Chem 2002;277:43549-52. (Pubitemid 36157766)
27. Hossain MS, Ozaki T, Wang H, Nakagawa A, Takenobu H, Ohira M, et al. N-MYC promotes cell proliferation through a direct transactivation of neuronal leucine-rich repeat protein-1 (NLRR1) gene in neuroblastoma. Oncogene 2008;27:6075-82.
28. Ishii N, Wanaka A, Tohyama M. Increased expression of NLRR-3 mRNA after cortical brain injury in mouse. Molecular Brain Research 1996;40:148-52. (Pubitemid 26241797)
29. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma. Diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77. (Pubitemid 23228250)
30. Matsumura T, Iehara T, Sawada T, Tsuchida Y. Prospective study for establishing the optimal therapy of infantile neuroblastoma in Japan. Med Pediatr Oncol 1998;31:210.
31. Kaneko M, Nishihira H, Mugishima H, Ohnuma N, Nakada K, Kawa K, et al. Stratification of treatment of stage 4 neuroblastoma patients based on N-myc amplification status. Study Group of Japan for Treatment of Advanced Neuroblastoma, Tokyo, Japan. Med Pediatr Oncol 1998;31:1-7. (Pubitemid 28243693)
32. Melino G, Thiele CJ, Knight RA, Piacentini M. Retinoids and the control of growth/death decisions in human neuroblastoma cell lines. J Neurooncol 1997;31:65-83. (Pubitemid 27077711)
33. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985;313:404-6. (Pubitemid 15198727)
34. Niizuma H, Nakamura Y, Ozaki T, Nakanishi H, Ohira M, Isogai E, et al. Bcl-2 is a key regulator for the retinoic acid-induced apoptopic cell death in neuroblastoma. Oncogene 2006;25:5046-55.
35. Bjelfman C, Meyerson G, Cartwright CA, Mellstrom K, Hammerling U, Pahlman S. Early activation of endogenous pp60src kinase activity during neuronal differentiation of cultured human neuroblastoma cells. Mol Cell Biol 1990;10:361-70.
36. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of a-prothymosin and ornithine decarboxylase and accelerates progression into S-phase after mitogenic stimulation of quiescent cells. Oncogene 1996;13:803-12. (Pubitemid 26312908)
37. Chen L, Peng Z, Bateman E. In vivo interactions of the Acanthamoeba TBP gene promoter. Nucleic acids Res 2004;32:1251-60. (Pubitemid 38854726)
38. Peukert K, Staller P, Schneider A, Carmichael G, Hanel F, Eilers M. An alternative pathway for gene regulation by Myc. EMBO J 1997;16:5672-86. (Pubitemid 27399859)
39. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The International Neuroblastoma Pathology Classification (the Shimada System). Cancer 1999;86:364-72. (Pubitemid 29327594)
40. Ikegaki N, Gotoh T, Kung B, Riceberg JS, Kim DY, Zhao H, et al. De novo identification of MIZ-1 (ZBTB17) encoding a MYC-interacting zinc-finger protein as a new favorable neuroblastoma gene. Clin Cancer Res 2007;13:6001-9. (Pubitemid 350075055)
41. Tang XX, Zhou H, Kung B, Kim DY, Hicks SL, Cohn SL, et al. The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res 2006;66:2826-33.
42. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002;2:764-76. (Pubitemid 37328911)
43. Levens DL. Reconstructing MYC. Genes dev 2003;17:1071-7. (Pubitemid 36534981)
44. Wanzel M, Herold S, Eilers M. Transcriptional repression by Myc. Trends Cell Biol 2003;13:146-50. (Pubitemid 36293787)
45. Shohet JM, Hicks MJ, Plon SE, Burlingame SM, Stuart S, Chen SY, et al. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res 2002;62:1123-8. (Pubitemid 34160297)
46. lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A. Id2 is a retinoblastoma protein target and mediates signaling by Myc oncoproteins. Nature 2000;407:592-8.
47. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A 2005;102:731-6. (Pubitemid 40282734)